Brief: Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results For AL001
22/06/2023 13:19
June 22 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO ANNOUNCES POSITIVE PHASE IIA CLINICAL TRIAL
RESULTS FOR AL001
* ALZAMEND NEURO -TOPLINE DATA IDENTIFIES MAXIMUM TOLERATED
DOSE
FROM PHASE IIA MULTIPLE ASCENDING DOSE STUDY FOR AL001
* ALZAMEND NEURO -PLANS TWO PHASE II CLINICAL TRIALS TO
INVESTIGATE SAFETY AND EFFICACY OF AL001 FOR PATIENTS WITH MILD
TO MODERATE ALZHEIMER'S DISEASE
Source text for Eikon: ID:nBwzWJWya
Further company coverage: ALZN.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview